Source:http://linkedlifedata.com/resource/pubmed/id/20166101
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2010-2-18
|
pubmed:abstractText |
Pancreatic resections are associated with high morbidity (30% to 60%) and mortality (5%). Synthetic analogues of somatostatin are advocated by some surgeons to reduce complications following pancreatic surgery, however their use is controversial.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
1469-493X
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
CD008370
|
pubmed:dateRevised |
2010-10-21
|
pubmed:meshHeading |
pubmed-meshheading:20166101-Humans,
pubmed-meshheading:20166101-Octreotide,
pubmed-meshheading:20166101-Pancreas,
pubmed-meshheading:20166101-Pancreatic Diseases,
pubmed-meshheading:20166101-Pancreatic Neoplasms,
pubmed-meshheading:20166101-Postoperative Complications,
pubmed-meshheading:20166101-Somatostatin
|
pubmed:year |
2010
|
pubmed:articleTitle |
Somatostatin analogues for pancreatic surgery.
|
pubmed:affiliation |
University Department of Surgery, Royal Free Hospital and University College School of Medicine, 9th Floor, Royal Free Hospital, Pond Street, London, UK, NW3 2QG.
|
pubmed:publicationType |
Journal Article,
Review,
Meta-Analysis
|